An open, 3-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or non-amplified estrogen receptor positive metastatic breast cancer
Latest Information Update: 02 Feb 2023
At a glance
- Drugs Lucitanib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus First in man; Therapeutic Use
- Acronyms FINESSE
- Sponsors IRIS; Servier
- 18 Jul 2022 Results of a Pop PK pooled analysis from five phase 1 and 2 clinical studies: NCT01283945, NCT02053636, ISRCTN23201971, NCT02202746 and NCT02109016 published in the European Journal of Drug Metabolism and Pharmacokinetics
- 18 Dec 2021 This trial has been completed in Italy, according to European Clinical Trials Database record,
- 16 Oct 2019 Primary endpoint has been met.